Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer

Autor: Cordula A. Jilg, Kathrin Reichel, Christian Stoykow, H. Christian Rischke, Mark Bartholomä, Vanessa Drendel, Moritz von Büren, Wolfgang Schultze-Seemann, Philipp T. Meyer, Michael Mix

Publikováno v: EJNMMI Research, Vol 10, Iss 1, Pp 1-13 (2020)

Abstract Purpose Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, referred to as [111In]PSM

Externí odkaz: https://doaj.org/article/3caf1d9e4cfc4126b623fb2a44837206

Results from extended lymphadenectomies with [ ¹¹¹ In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer.

Autor: Jilg CA; Department of Urology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstraße 55, 79106, Freiburg, Germany. cordula.jilg@uniklinik-freiburg.de., Reichel K; Department of Urology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstraße 55, 79106, Freiburg, Germany., Stoykow C; Department of Nuclear Medicine, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Rischke HC; Department of Radiation Oncology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Bartholomä M; Department of Nuclear Medicine, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Drendel V; Institute for Pathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany., von Büren M; Department of Urology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstraße 55, 79106, Freiburg, Germany., Schultze-Seemann W; Department of Urology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstraße 55, 79106, Freiburg, Germany., Meyer PT; Department of Nuclear Medicine, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany., Mix M; Department of Nuclear Medicine, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Department of Medical Imaging and Clinical Oncology, Nuclear Medicine Division, Faculty of Medicine and Health Science, Stellenbosch University, Stellenbosch, South Africa.

Publikováno v: EJNMMI research [EJNMMI Res] 2020 Mar 06; Vol. 10 (1), pp. 17. Date of Electronic Publication: 2020 Mar 06.